(NU/1433-47) Kargenera: The Provision of Business Consultancy to Assist Commercialisation of University Research

The University of Southampton have developed a unique DNA based therapeutic to activate NK cells against cancer. The therapeutic is delivered intramuscularly in combination with DNA encoding the potent immune stimulating cytokine IL-15. The objective is for an Executive to jointly work with the team to bring the opportunity towards and ultimately achieve launch of a new spinout company. The project description is included below: Phase 1 Opportunity Validation and Business Plan Creation - Executive leads all activit...